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Received August 29, 2015; accepted February 1, 2016AbstractBackground: It is uncertain whether adjuvant chemotherapy (CMT) improves survival in patients with low-risk Stage II colon cancer. We aimed
to determine the disease-free survival (DFS) and 5-year overall survival (OS) of low-risk Stage II colon cancer patients treated with adjuvant
tegafur/uracil (UFUR).
Methods: From January 2004 to December 2011, the follow-up status of 278 low-risk Stage II colon cancer patients who underwent surgery in a
single medical center was retrospectively analyzed. These patients were divided into three groups based on whether they received adjuvant CMT
with UFUR, adjuvant CMT with 5-fluorouracil, or surgery alone. DFS and 5-year OS curves were calculated using KaplaneMeier survival
analysis and Cox proportional hazards regression.
Results: In the study population, including 278 low-risk Stage II colon cancer patients with a mean age of 68.28 ± 13.01 years, 132 (47.5%)
received adjuvant CMTwith UFUR, 49 (17.6%) received adjuvant CMTwith 5-fluorouracil, and 97 (34.9%) underwent radical surgery alone. At
5 years, the adjusted DFS and OS of low-risk Stage II colon cancer patients were 85.5% and 81.8%, respectively, in the surgery alone group and
97.9% and 96.2%, respectively, in the surgery plus UFUR > 12 months group ( p ¼ 0.004 and p ¼ 0.098, respectively). In multivariate analysis,
CMT with UFUR for more than 12 months increased DFS over surgery alone. There was no statistical difference in the 5-year OS.
Conclusion: Adjuvant CMT treatment of low-risk Stage II colon cancer patients with UFUR for more than 12 months following surgery im-
proves DFS over surgery alone.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Radical surgical resection is the primary treatment for
patients with locoregional colon cancer [negative lymph nodeConflicts of interest: The authors declare that they have no conflicts of interest
related to the subject matter or materials discussed in this article.
* Corresponding author. Dr. Shu-Wen Jao, Division of Colorectal Surgery,
Department of Surgery, Tri-Service General Hospital, 325, Section 2,
Cheng-Kung Road, Taipei 114, Taiwan, ROC.
E-mail address: Jeminghu@gamil.com (S.-W. Jao).
http://dx.doi.org/10.1016/j.jcma.2016.04.001
1726-4901/Copyright © 2016, the Chinese Medical Association. Published by El
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(LN) Stage I, II disease]; such patients have a good prognosis,
with a 5-year overall survival (OS) of approximately 80% after
radical surgery alone.1,2 Chemotherapy (CMT) drugs are
administered as systemic therapy for colon cancer patients
with positive LNs and distal metastasis. However, there is no
definite consensus on the role of adjuvant CMT for Stage II
colon cancer, especially in low-risk patients. In our patient
database, the routine consecutive administration of tegafur/
uracil (UFUR) as adjuvant CMT has provided good disease-
free survival (DFS) and 5-year OS in patients with low-risk
Stage II colon cancer, especially with treatment for moresevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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and 5-year OS rates for low-risk Stage II colon cancer patients
after radical surgery.
The American Society of Clinical Oncology (ASCO) and the
National Comprehensive Cancer Network (NCCN) treatment
guidelines do not recommend the routine use of adjuvant CMT
for Stage II colon cancer patients. ASCO and NCCN guidelines
state that adjuvant CMT can be considered for patients with
high-risk factors, including T4 tumors leading to obstruction,
perforation, and poor differentiation, and for patients with fewer
than 12 positive LNs.3,4 Some published studies support the use
of adjuvant CMT following surgery, as it provides a survival
benefit over surgery alone,5e8 while others have supported
adjuvant CMT only for high-risk Stage II colon cancer
patients.9e13 However, most of these studies included mixed-
Stage II cancers (low-risk and high-risk Stage II colon cancer
patients), and not all of these studies provide a separate analysis
of survival benefit for patients with low-risk Stage II colon
cancer treated with adjuvant UFUR CMT. Some studies have
addressed the question of whether to use adjuvant CMT for low-
risk Stage II colon cancer. However, clinical trials have not
demonstrated that adjuvant CMT improves survival for patients
with resected low-risk Stage II colon cancer. Thus, its routine
use in these patients has been controversial.3 The purpose of this
study was to investigate the survival outcome with UFUR as
adjuvant CMT for low-risk Stage II colon cancer patients.
2. Methods2.1. Patient selectionFrom January 2004 to December 2011, a total of 2809
colon cancer patients underwent operation at our hospital (Tri-
Service General Hospital, Taipei, Taiwan). Clinical data were
extracted from the retrospectively collected Cancer Registry
Group, Tri-Service General Hospital. The surgical and path-
ological findings were recorded according to the 6th/7th
American Joint Committee on Cancer (AJCC)/Union for In-
ternational Cancer Control tumor-node-metastasis (TNM)
classification. All operations were performed by colorectal
surgeons in our hospital.
There were 535 patients with Stage II colon cancer in our
hospital based on the pathology, according to the 6th/7th AJCC
staging system. Those who underwent curative surgical
intervention alone or surgery plus adjuvant CMT [UFUR or 5-
fluorouracil (5-FU)] were enrolled in this study. Patients with
any of the following criteria were excluded: (1) rectal cancer;
(2) pathological diagnosis of positive surgical margins; (3)
synchronous or metachronous double cancer; (4) synchronous
or metachronous multiple colon cancer; (5) inflammatory
bowel disease or hereditary colon cancer syndromes; (6) pre-
vious history of malignancy; (7) lack of an entire treatment
course in our hospital; (8) perioperative (<30 days post-
operation) mortality; (9) lack of follow-up data; or (10)
incomplete oral adjuvant therapy (<3 months). Data on
approximately 9.5% of patients was incomplete, and hence,
these data were removed from the database. A total of 403patients with Stage II colon cancer were included in this
retrospective analysis. They were divided into three non-
randomized groups: those who underwent surgery alone, sur-
gery plus adjuvant CMT with UFUR, and surgery plus
adjuvant CMT with 5-FU. In total, 175 Stage II colon cancer
patients received UFUR as adjuvant CMT following surgery,
including 132 low-risk patients.
After a potentially curative operation, the decision of
whether or not to administer adjuvant CMT depended on the
patients decision, the clinical judgment of the attending phy-
sicians, and our multidisciplinary team meeting, which was
based on the general performance of the patient, their patho-
logic features, and operative condition. All of the patients in
this study agreed to receive oral UFUR or infusional 5-FU
after a discussion on the potential morbidity and benefits
after treatment.
Seventy-three Stage II colon cancer patients received infu-
sional 5-FU-based adjuvant CMTover 6months. The regimen of
infusional 5-FU-based CMT included high-dose 5-FU (425 mg/
m2/d) plus leucovorin (30 mg/m2/d), as either a monthly 5-day
course or a weekly 1-day course for a period of 6 months. In
the UFUR group, patients receiving 5-FU prodrug capsules
(UFUR; 100 mg/capsule) administered at 4 capsules/d (2 cap-
sules twice a day) within the 1-month postoperative period at the
initial dose were considered adjuvant therapy recipients.
The protocol treatment was discontinued when the first
recurrence was confirmed or when the side effects or toxicity
were not tolerated. A dose reduction was implemented when
the white blood cell count was <3000/mm3, platelets were
<100,000/mm3, absolute neutrophil count was <1500, and
aspartate aminotransferase and/or alanine transaminase levels
were more than three times higher than the upper limit of the
normal range. None of the patients received preoperative CMT
or radiotherapy.
The database included: (1) patient demographic informa-
tion, including their name, sex, age, family history, levels of
tumor markers such as carcinoembryonic antigen (CEA), and
carbohydrate-antigen 19-9 (CA19-9); and (2) characteristics of
the tumor, including the location, gross appearance, TNM
stage, and important pathologic prognostic features, such as
the number of LNs examined, differentiation, lymphovascular
space invasion (LSI), tumor size, and the invasion pattern of
the cancerous tissue and mucinous component.2.2. Follow upAccording to the NCCN treatment guidelines, all patients
had a regular follow up consisting of visits at 3-month in-
tervals for the first 2 years, 6-month intervals for up to 4 years,
and annually thereafter. The follow-up examinations included
a physical examination, rectodigital examination, blood
chemistry panel (such as complete blood cell count and CEA,
CA19-9 levels, and liver function tests), radiographs of the
thorax, and abdominal sonograms. A colonoscopy was per-
formed annually. If recurrence was suspected, further testing,
such as a chest computed tomography scan, whole-body bone
scan, or even a whole-body positron emission tomography
Table 1
Clinicopathological distribution of total Stage II colon cancer patients included in the analyses stratified by their characteristics and treatment group.
Surgery alone (n ¼ 155) Surgery plus UFUR (n ¼ 175) Surgery plus 5-FU (n ¼ 73) p
n (%) n (%) n (%)
Age (y), mean (SD) 74.17 (12.13) 67.69 (11.26) 57.14 (11.08) <0.001
70 y 48 (30.97) 101 (57.71) 63 (86.30) <0.001
>70 y 107 (69.03) 74 (42.29) 10 (13.70)
Sex 0.858
Male 83 (53.55) 99 (56.57) 40 (54.79)
Female 72 (46.45) 76 (43.43) 33 (45.21)
Risk factor 0.149a
Without risk factor 97 (62.58) 132 (75.43) 49 (67.12)
With 1 risk factor 46 (29.68) 35 (20.00) 19 (26.03)
With >1 risk factor 12 (7.74) 8 (4.57) 5 (6.85)
Location of primary tumor 0.178
Cecum 16 (10.32) 18 (10.29) 8 (10.96)
Ascending colon 35 (22.58) 34 (19.43) 25 (34.25)
Transverse colon 17 (10.97) 27 (15.43) 6 (8.22)
Descending colon 14 (9.03) 19 (10.86) 12 (16.44)
Sigmoid colon 56 (36.13) 62 (35.43) 18 (24.66)
Rectosigmoid 17 (10.97) 15 (8.57) 4 (5.48)
Location of primary tumor 0.985
Right 65 (41.94) 74 (42.29) 30 (41.10)
Left 90 (58.06) 101 (57.71) 43 (58.90)
Obstruction 0.249a
Without obstruction 146 (94.19) 170 (97.14) 68 (93.15)
With obstruction 9 (5.81) 5 (2.86) 5 (6.85)
NLR, mean (SD) 6.38 (7.23) 4.71 (8.31) 5.53 (5.22) 0.145
CRM
Proximal (cm), mean (SD) 6.66 (5.06) 7.00 (5.01) 7.53 (7.25) 0.675
Distal (cm), mean (SD) 6.12 (5.52) 6.74 (5.88) 8.09 (7.23) 0.192
CEA (ng/mL), mean (SD) 5.21 (7.04) 6.21 (16.35) 13.55 (37.97) 0.034
5 83 (73.45) 139 (82.25) 31 (67.39) 0.054
>5 30 (26.55) 30 (17.75) 15 (32.61)
CA19-9 (U/mL), mean (SD) 36.72 (97.15) 18.51 (21.98) 57.46 (136.88) 0.012
25 65 (70.65) 115 (75.66) 25 (67.57) 0.508
>25 27 (29.35) 37 (24.34) 12 (32.43)
Tumor size (mm), mean (SD) 49.63 (20.54) 51.16 (25.17) 62.72 (27.79) <0.001
49 82 (53.25) 94 (53.71) 23 (31.94) 0.004
>49 72 (46.75) 81 (46.29) 49 (68.06)
Gross appearance 0.054
Polypoid 47 (36.72) 51 (31.48) 29 (49.15)
Ulcerative 81 (63.28) 111 (68.52) 30 (50.85)
Histopathological classification 0.893
Not poorly differentiated 143 (92.26) 160 (91.43) 66 (90.41)
Poorly differentiated 12 (7.74) 15 (8.57) 7 (9.59)
Lymphovascular space invasion (LSI) 0.024a
Without LSI 142 (97.93) 169 (98.83) 56 (91.80)
With LSI 3 (2.07) 2 (1.17) 5 (8.20)
LNs (Z), mean (SD) 15.30 (5.66) 16.03 (5.26) 18.70 (6.66) <0.001
<12 37 (23.87) 22 (12.57) 2 (2.74) <0.001
12 118 (76.13) 153 (87.43) 71 (97.26)
Perineural invasion 0.186a
Without invasion 137 (96.48) 163 (98.79) 58 (95.08)
With invasion 5 (3.52) 2 (1.21) 3 (4.92)
Assessed by one-way analysis of variance or by Chi-square test.
CA ¼ cancer antigen; CEA ¼ carcinoembryonic antigen; CRM ¼ circumferential resection margin; LN ¼ lymph node; NLR ratio ¼ neutrophil to lymphocyte
ratio; SD ¼ standard deviation; UFUR ¼ tegafur/uracil; 5-FU ¼ 5-fluorouracil.
a Fisher's exact test.
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definition of recurrence included a recurrent lesion that was
confirmed pathologically or that showed progressively
increasing size in image studies.The 5-year OS time was measured from the date of the
operation to the date of last visit or death. DFS was counted
from the date of the operation to the date of confirmation of
recurrence.
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tion of CMT to curative surgical resection conferred an
improvement in 5-year DFS and OS for patients with AJCC
Stage II colon cancer. Analyzed factors included age
(70 years or >70 years), sex, presence of risk factors,
location of primary tumor (cecum, ascending colon, transverse
colon, descending colon, sigmoid colon, or rectosigmoid),
presence of an obstruction, histopathological classification
(well, moderately, or poorly differentiated), tumor size
(49 mm, or >49 mm), CEA level (5 ng/mL, or >5 ng/mL),
CA19-9 level (25 U/mL, or >25 U/mL), presence of LSI,
presence of perineural invasion, and the number of LNs
examined (1e11 or >12).
IBM SPSS statistics software version 22 (IBM SPSS Sta-
tistics 22, Asia Analytics Taiwan Ltd., Taipei, Taiwan) was
used for data entry and statistical analysis. Each variable factor
of the 5-year OS and DFS rates was estimated using the
KaplaneMeier method. The significance of the differences
between subgroups was calculated using the log-rank test. The
variables that reached statistical significance ( p < 0.05) were
entered into multivariate analysis, which was performed using
the Cox proportional hazard model. All statistical tests were
two-tailed, and a p value < 0.05 was considered to be statis-
tically significant.2.4. Ethics statementThis retrospective study has been approved by the Institu-
tional Review Board of Tri-Service General Hospital
(Taiwan). No informed consent was given because the data
were analyzed anonymously.
3. Results3.1. Patient demographicsAfter the exclusion of 132 patients, 403 individuals with
Stage II colon cancer were initially enrolled in our study and
stratified into three subgroups: (1) 155 (38.5%) patients who
underwent surgery alone; (2) 175 (43.4%) who underwent
surgery and also received adjuvant CMT with oral UFUR;
and (3) 73 (18.1%) who underwent surgery plus received
adjuvant CMT with infusional 5-FU. The distribution of pa-
tients by their demographic characteristics is shown is Table
1. The patient population included 222 men (54.9%) and 181
women (45.1%). With regard to tumor location, 170 (42.1%)
patients were right colon carcinomas and 233 (57.9%) were
left colon carcinomas. In this series, the average number of
examined LNs in each specimen was 16.24 ± 5.80 (range,
3e43). In 61 specimens (15.1%), the number of LNs exam-
ined was <12. Within the median 53-month follow-up period,
recurrence developed in 36 patients (8.18%). When the three
treatment groups (surgery alone, surgery plus UFUR, and
surgery plus 5-FU) were compared, there were no differences
in sex, with or without risk factors, location of primarytumor, primary tumor size ( 49mm, or >49 mm), presence
of LSI, presence of perineural invasion, CEA or CA-199
level, histopathological classification, gross appearance, and
the number of LNs examined. There was no postoperative
mortality.
Patients with at least one risk factor (i.e., T4 lesion, LSI,
obstruction at presentation, or the number of LNs examined
was <12) were considered as the high-risk group. We further
examined our data to see if patients who had more risk factors
had poorer DFS. Three subgroups of risk factors (no risk factor,
one risk factor, and more than one risk factor) significantly
distinguished differences in the 5-year DFS and OS (DFS,
92.1%, 81.7%, and 79.2%, respectively, p ¼ 0.003; and 5-year
OS, 90.7%, 83.3%, and 80.8%, respectively, p ¼ 0.007; Fig. 1).
Two hundred forty-eight patients (61.5%) received adjuvant
CMT, either orally or intravenously. There was a significant
difference in the 5-year DFS and 5-year OS between the Stage
II colon cancer patients who did and did not receive adjuvant
CMT (DFS, 91.0% and 84.2%, respectively, p ¼ 0.01; and 5-
year OS, 92.6% and 80.1%, respectively, p < 0.001; Figs. 2
and 3). The data for low-risk Stage II colon cancer patients
showed the same results (DFS, 94.8% and 85.8%, respectively,
p ¼ 0.013; and 5-year OS, 94.8% and 81.8%, respectively,
p ¼ 0.006; Figs. 2 and 3).
These results demonstrate a significant survival benefit of
adjuvant CMT for low-risk patients with Stage II colon cancer
in terms of 5-year DFS (surgery alone vs. surgery plus UFUR
vs. surgery plus 5-FU: 85.8% vs. 97.5% vs. 88.5%, respec-
tively, p ¼ 0.004; Fig. 4A) and 5-year OS (surgery alone vs.
surgery plus UFUR vs. surgery plus 5-FU: 81.8% vs. 93.5%
vs. 97.8%, respectively, p < 0.017; Fig. 4B).
Among the total Stage II colon cancer patients, we strati-
fied them into three subgroups: surgery alone, surgery fol-
lowed by adjuvant UFUR for less than <1 year, and surgery
adjuvant UFUR for >1 year. All of the patients were followed
up. The reasons for not reaching the initial prescribed dose
included recurrence during the treatment period, adverse re-
actions, and complications. The duration of adjuvant CMT
with UFUR was evaluated in the same manner as the survival
benefits for 5-year DFS and 5-year OS for the low-risk pa-
tients. The subgroup of patients treated with adjuvant CMT
with UFUR for more than 12 months had a significant benefit
in terms of DFS over the surgery alone subgroup (surgery
alone vs. surgery plus UFUR  12 months vs. surgery plus
UFUR > 12 months: 85.8% vs. 97.0% vs. 97.9%, p ¼ 0.004;
Fig. 5B), but it was not statistically significant for 5-year OS
(surgery alone vs. surgery with UFUR  12 months vs. sur-
gery with UFUR > 12 months: 81.8% vs. 86.2% vs. 96.2%,
p ¼ 0.098; Fig. 6B).
The univariate and multivariate analyses for DFS and 5-
year OS of low-risk Stage II colon cancer are shown in
Tables 2 and 3, respectively. In univariate analysis, only
adjuvant CMT with UFUR > 12 months [hazard ratio
(HR) ¼ 0.08, 95% confidence interval, 0.01e0.65, p ¼ 0.018]
were good prognostic factors that significantly influenced 5-
year DFS over that of the surgery alone group (Table 2).
Similarly, age  70 years, and adjuvant CMT with UFUR >
Fig. 1. Stage II colon cancer with more than one risk factor is associated with: (A) poorer disease-free survival (DFS; p ¼ 0.003); and (B) 5-year overall survival
( p ¼ 0.007).
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p ¼ 0.043) were significantly associated with 5-year OS (Table
3). Multivariate analysis showed that only adjuvant CMT >
12 months (HR ¼ 0.12, 95% confidence interval, 0.01e0.94;
p ¼ 0.044) was associated with better 5-year DFS. Moreover,
age, sex, tumor size, gross appearance, and surgical margin
were not associated with DFS for low-risk Stage II colon
cancer patient (Tables 2 and 3).3.2. RecurrenceDisease recurrence occurred in 36 patients (8.18%); most of
these cases (31 patients, 86.1%) had distant metastases. Only
five patients (13.8%) had a local recurrence around the anas-
tomosis site. The distant metastases were mainly to the liver
(18 patients, 50%) and the lungs (12 patients, 33.3%). In our
study, the mean recurrence time was 28.9 months; 69% of
Fig. 2. Comparison of disease-free survival (DFS) between surgery alone and surgery with adjuvant chemotherapy. (A) Total Stage II colon cancer patients; (B)
low-risk Stage II colon cancer patients.
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within 3 years postoperation.3.3. ToxicityThe incidence of nausea/vomiting, skin lesions, oral ulcers,
and neutropenia was 4% in the surgery plus UFUR group,
and there was no significant difference in the incidence of
toxicities between the surgery alone and surgery plus UFUR
groups. The most common side effects were severe nausea and
anorexia.
4. Discussion
In Taiwan, colorectal cancer is the most common cancer
and the third most frequent cause of cancer-related death,14
accounting for an estimated 5698 deaths in 2012.15 With theincrease in the implementation of fecal occult blood test and
screening colonoscopies performed in Taiwan, an increasing
number of earlier Stage II colon cancer cases have been
detected, representing an estimated 18e20% of the new
colorectal cancer cases in our hospital database. From the
Annual Cancer Report from Taiwan Cancer Registration
System, 5-year OS for patients with Stage II approximates
71.3%.15 To give the best possible care for more and more
low-risk Stage II colon cancer patients, aggressive treatment
guidelines are very important.
In this study, we set DFS and 5-year OS as the primary
endpoints of evaluation to determine the effects conferred by
adjuvant CMT on patients with Stage II colon cancer. Of
these patients, multivariate analysis showed that adjuvant
CMT with UFUR > 12 months was associated with improved
DFS. Moreover, age  70 years and CMT with UFUR >
12 months were associated with improved 5-year OS. We
Fig. 3. Comparison of 5-year overall survival between surgery alone and surgery with adjuvant chemotherapy. (A) Total Stage II colon cancer patients; (B) low-risk
Stage II colon cancer patients.
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by the NCCN guidelines16 and found that three subgroups of
risk factors (no risk factor, 1 risk factor, and >1 risk factor)
could distinguish significantly different DFS and 5-year OS
rates. We further examined our database to see if patients
who had more risk factors had poorer DFS and 5-year OS.
For patients without any risk factors, the 5-year DFS could be
more than 92.1%. However, the 5-year DFS for patients with
one or more risk factors was only 79.2% ( p ¼ 0.003). The 5-
year OS could be more than 90.7% for patients without any
risk factors and only 80.8% for patients with one or more risk
factors ( p ¼ 0.003). According to a report from an ASCO
panel that reviewed the literature prior to May 2003, routine
adjuvant CMT was not recommended as standard therapy for
Stage II colon cancer, with the panel citing a possible 2e4%
increase in absolute survival, which was not a statistically
significant improvement.3 Some studies also concluded that
for Stage II colon cancer patients, either with or without poorprognostic features, there may be no survival benefit from
adjuvant CMT.17
However, McKenzie et al7 determined that adjuvant CMT
improved OS in patients with Stage II colon cancer
(HR ¼ 0.88; 95% confidence interval, 0.78e0.99; p ¼ 0.031).
Later, another study reported that patients in a high-risk group
(n ¼ 484) with one or more risk factors who had received
adjuvant CMT had a significantly improved prognosis
compared with those in a high-risk group who did not receive
adjuvant CMT (DFS with and without adjuvant therapy, 87.3%
vs. 78.9%, p ¼ 0.028), but not to low-risk patients.8 Study of
pooled analyses of more than 20,800 patients from 18 trials
revealed that adjuvant CMT provided significant a DFS
benefit, primarily by reducing the recurrence rate, within the
first 2 years of adjuvant therapy, with some benefit in Years
3e4, translating into a long-term 5-year OS benefit.18 Our
results support the conclusions of these previous studies, as
patients receiving adjuvant CMT showed improved DFS and
Fig. 4. Survival benefit of adjuvant chemotherapy for low-risk Stage II colon cancer patients compared between three subgroups of chemotherapy courses. (A)
disease-free survival (DFS); (B) 5-year overall survival. UFUR ¼ tegafureuracil; 5-FU ¼ 5-fluorouracil.
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patients presenting without high-risk factors.
In several studies, bowel obstruction or tumor perforation at
initial presentation have been identified as poor prognostic
factors, because they enable the spread of tumor cells via the
blood and the seeding of tumor cells in the peritoneal cavity.19
The interpretation of these results, however, is complicated, as
patients presenting with perforation or other complications of
colon cancer tend to have a higher incidence of metastatic
disease, higher disease stage, and greater residual tumor
burden. According to our data, patients without obstruction
had improved DFS but not 5-year OS. The ASCO guidelines
indicate that a preoperative serum CEA level > 5 ng/mL is
associated with a poor prognosis. However, our data did not
confirm these results; this finding could be attributed to the
small number of patients in this subgroup.
Most clinicians in Korea and Japan tend to prescribe
adjuvant CMT for low-risk Stage II colon cancer patients. Theaim of adjuvant CMT is to eradicate micrometastases and
increase the 5-year OS; however, there seems to be no sig-
nificant evidence to support the presence of micrometastases
in low-risk Stage II colon cancer. Some reports have shown
that survival is slightly superior for CMT-treated patients
(range, 2e4%), but others have reported that the differences
were not statistically significant.2,20,21 A standard for post-
operative adjuvant CMT in low-risk Stage II colon cancer has
not yet been established.
To date, many genetic signature studies have important
implications. Some geneticists recommended that patients
with elevated microsatellite alterations at selected tetranu-
cleotide repeats colorectal cancer (hMutSb defective) had
diminished response to adjuvant 5-FU chemotherapy.22
However, the latest study concluded that adjuvant 5-FU-
based chemotherapy has improved survival benefit for Stage II
colorectal cancer patients regardless of elevated microsatellite
alterations at selected tetranucleotide status. In terms of the
Fig. 5. Comparison of disease-free survival (DFS) between surgery alone and surgery with adjuvant chemotherapy with tegafureuracil (UFUR) for less than and
more than 1 year. (A) Total Stage II colon cancer patients; (B) low-risk Stage II colon cancer patients.
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reached a deadlock.23,24 Lin et al5 have shown similar thera-
peutic efficacies for 5-year OS and recurrence with infusional
5-FU and oral UFUR. A pooled analysis in our study, which
included 278 low-risk Stage II colon cancer patients, indicated
that adjuvant CMTwith oral UFUR for low-risk Stage II colon
cancer significantly improves DFS compared with 5-FU
( p ¼ 0.004), but not for 5-year OS ( p ¼ 0.017). It is
possible that the use of long-term adjuvant CMT with UFUR
and maintaining the serum concentration destroys microscopic
deposits of cancer cells in the surgical field or hidden distant
metastases, thereby decreasing the recurrence rate.25Our results also illustrate the following important concept
for the management of low-risk Stage II colon cancer: adju-
vant UFUR treatment for more than 12 months actually
eradicates colon cancer cells, thereby curing patients, pro-
longing survival, and reducing relapses. Analysis of our data,
which included 132 low-risk patients who received adjuvant
CMT with UFUR, indicates that treatment for more than
12 months significantly improves 5-year DFS over that of the
surgery-alone group ( p ¼ 0.004); however, the results were
not statistically significant for 5-year OS ( p ¼ 0.098). The 5-
year DFS was 97.0% in the surgery plus UFUR  12 months
group and 97.9% in the surgery plus UFUR > 12 months
Fig. 6. Comparison of 5-year overall survival between surgery alone and surgery with adjuvant chemotherapy with tegafureuracil (UFUR) for less than and more
than 1 year. (A) Total Stage II colon cancer patients; (B) low-risk Stage II colon cancer patients.
486 J.-M. Hu et al. / Journal of the Chinese Medical Association 79 (2016) 477e488group, and there was no statistical difference. According to our
analysis, we believe that oral UFUR as adjuvant CMT pro-
vides 5-year OS benefits. However, our data did not confirm
these results; this finding could be attributed to the small
number of patients in this subgroup.
According to the national conditions and culture in Taiwan,
oral adjuvant CMTwith UFUR is preferable over the infusional
form, and patients with low-risk Stage II colon cancer can easily
be administered the therapy. The National Health Insurance Act
in Taiwan has offered coverage for UFUR as adjuvant CMT for
Stage II colon cancer since 2003. There are more and morepatients receiving routine adjuvant CMT with UFUR after
resection of low-risk Stage II colon cancer in Taiwan; according
to our data, UFUR was administered to 47.5% (132/278) of the
patients with low-risk Stage II colon cancer.
In the current study, no Grade 3 or greater toxicity attrib-
utable to the consecutive administration of UFUR was
observed. A minority of the patients wished to discontinue
treatment due to adverse reactions, and others suffered from
complications. Although there is a possibility of experiencing
side effects, it is still worth trying this therapy to reduce the
risk of recurrence.
Table 2
Prognostic factors for disease-free survival in the low-risk Stage II colon
cancer patients (n ¼ 278).
Variables Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age
70 y 1.00 1.00
>70 y 1.50 0.61e3.70 0.378 2.07 0.54e8.04 0.292
Sex
Male 1.00
Female 0.59 0.22e1.56 0.285 e
CEA
5 1.00
>5 0.43 0.06e3.40 0.425 e
CA19-9
25 1.00
>25 0.03 0.00e18.46 0.287 e
Tumor size (mm)
49 1.00
>49 1.27 0.48e3.35 0.624 e
Gross appearance
Polypoid 1.00
Ulcerative 2.01 0.55e7.30 0.291 e
CRM, proximal
2 cm 1.00
>2 cm 0.95 0.21e4.38 0.952 e
CRM, distal
2 cm 1.00
>2 cm 2.53 0.33e19.60 0.375 e
NLR 1.06 1.00e1.12 0.057 1.04 0.98e1.11 0.195
Chemotherapy
No 1.00 1.00
UFUR  12 mo 0.20 0.03e1.57 0.127 0.25 0.03e1.98 0.189
UFUR > 12 mo 0.08 0.01e0.65 0.018 0.12 0.01e0.94 0.044
CA ¼ cancer antigen; CEA ¼ carcinoembryonic antigen; CI ¼ confidence
interval; CRM ¼ circumferential resection margin; HR ¼ hazard ratio; NLR
ratio ¼ neutrophil-to-lymphocyte ratio; UFUR ¼ tegafur/uracil.
Table 3
Prognostic factors for overall survival in the low-risk Stage II colon cancer
patients (n ¼ 278).
Variables Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age
70 y 1.00 1.00
>70 y 4.29 1.54e11.92 0.005 3.59 1.17e11.04 0.026
Sex
Male 1.00
Female 0.55 0.21e1.44 0.220 e
CEA
5 1.00
>5 1.46 0.46e4.59 0.519 e
CA19-9
25 1.00
>25 1.80 0.60e5.42 0.296 e
Tumor size (mm)
49 1.00
>49 1.20 0.48e2.98 0.695 e
Gross appearance
Polypoid 1.00
Ulcerative 1.05 0.39e2.84 0.923 e
CRM, proximal
2 cm 1.00
>2 cm 1.13 0.25e5.15 0.871 e
CRM, distal
2 cm 1.00
>2 cm 1.52 0.34e0.76 0.580 e
NLR 1.04 0.98e1.11 0.198 e
Chemotherapy
No 1.00 1.00
UFUR 12 mo 0.58 0.16e2.08 0.404 0.66 0.18e2.38 0.527
UFUR >12 mo 0.31 0.10e0.97 0.043 0.38 0.12e1.20 0.098
CA ¼ cancer antigen; CEA ¼ carcinoembryonic antigen; CI ¼ confidence
interval; CRM ¼ circumferential resection margin; HR ¼ hazard ratio; NLR
ratio ¼ neutrophil-to-lymphocyte ratio; UFUR ¼ tegafur/uracil.
487J.-M. Hu et al. / Journal of the Chinese Medical Association 79 (2016) 477e488The results of this study suggest that: (1) only receiving
adjuvant CMT with UFUR > 12 months is associated with
improved DFS in low-risk Stage II colon cancer patients; and
(2) age  70 years and adjuvant CMT with
UFUR > 12 months may provide a survival benefit in low-risk
Stage II colon cancer with improved OS. In this study, the
effect of an oral UFUR course was examined, and although the
number was small, an obvious improvement in DFS and a
borderline improvement 5-year OS for low-risk Stage II colon
cancer were observed in the >12 month treatment subgroup.
In conclusion, based on its improved survival profile, long-
course oral UFUR has the potential to replace short-course
infusional 5-FU/leucovorin as the standard adjuvant CMT
for patients with low-risk Stage II colon cancer. Our results
show that the routine consecutive administration of UFUR
(400 mg/d) as adjuvant CMT after radical surgery provides
improved DFS in patients with low-risk Stage II colon cancer,
especially administration for more than 12 months. To achieve
best DFS benefit, we suggest adjuvant CMT treatment of low-
risk Stage II colon cancer patients with UFUR for more than
12 months following surgery over surgery alone. The present
study had some limitations. It was conducted at a single
center, had a retrospective design, and lacked randomization.Whether or not adjuvant CMT was administered after a
potentially curative operation depended on the clinical judg-
ment of the attending physicians. An additional randomized
study is necessary to clarify the role of adjuvant therapy in
low-risk Stage II colon cancer patients.
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